Scinai Immunotherapeutics Successfully Meets Nasdaq Minimum Bid Price Requirements After Regulatory Review #NASDAQ #Scinai_Immunotherapeutics #Israel #Jerusalem #Biopharmaceutical
@newsen.bsky.socialExplore
@newsen.bsky.social@newsen.bsky.socialScinai Immunotherapeutics Shifts Focus to NanoAb and CDMO Growth Strategies #Scinai_Immunotherapeutics #Israel #Jerusalem #CDMO #NanoAb_Platform